Analyst firms · Citigroup · KRYS
Citigroup KRYS price target and rating history
Krystal Biotech Inc. (KRYS) · Health Care
Citigroup rates Krystal Biotech Inc. (KRYS) Buy with a $309 price target, as of its latest action on Jan 6, 2026. It has published 3 rating actions on KRYS since October 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a KRYS price target in the last 12 months, the median target is $400. Citigroup's $309 is 23% below that.
- Current rating
- Buy
- Price target
- $309
- Median target, all firms
- $400
- Actions on KRYS
- 3
Citigroup price target on KRYS
Every Citigroup rating on KRYS
- Jan 6, 2026
- Aug 6, 2024
- Oct 12, 2023
How other firms rate KRYS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Goldman Sachs | Buy | $441 | Sep 24, 2026 |
| RBC Capital Markets | Outperform | $400 | Aug 14, 2026 |
| Wolfe Research | Peer Perform | Mar 27, 2026 | |
| Citigroup | Buy | $309 | Jan 6, 2026 |
Questions about Citigroup and KRYS
- What is Citigroup's price target for KRYS?
- Citigroup's latest stated price target for Krystal Biotech Inc. (KRYS) is $309, from its action on Jan 6, 2026.
- What is Citigroup's rating on KRYS?
- Citigroup rates KRYS Buy, a bullish rating, as of Jan 6, 2026.
- When did Citigroup last change its view on KRYS?
- On Jan 6, 2026, Citigroup upgrades to Buy from Neutral, price target $309.
- How does Citigroup's KRYS target compare with other analysts?
- Across 3 firms with a KRYS price target in the last 12 months, the median target is $400. Citigroup's $309 is 23% below that.
More KRYS rating histories
All Citigroup ratingsKRYS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.